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Despite diagnostic and therapeutic improvements, 
cardiogenic shock (CS) is still the most common cause of 
death in patients with acute myocardial infarction. 
Although percutaneous coronary intervention (PCI), 
inotropes, ﬂ   uids, adjunctive medication, intra-aortic 
balloon pump (IABP), and ventricular assist devices are 
widely available, mortality rates in patients with CS 
remain high (40% to 50%). Th  erefore, Munsterman and 
colleagues [1], whose investigation of the micro  circu-
lation in patients with IABP was reported in the previous 
issue of Critical Care, have addressed an important topic.
In the last ﬁ  ve years, an important body of knowledge 
showing the pathophysiological importance of the micro-
circulation in the development of multiple organ failure 
in critically ill patients has been built up. Th   is has been 
made possible because of the development of novel 
techniques to either directly visualize or indirectly 
evaluate microvascular perfusion [2]. In CS, micro  vas-
cular alterations have been observed, resulting in a 
decrease of vessel density, the proportion of perfused 
capillaries, or microvascular ﬂ  ow [3,4]. Diﬀ  erent treat-
ment strategies, including pharmacological interventions 
and mechanical assist devices, may lead to microcircu-
latory improvement in CS [5-7].
In their article, Munsterman and colleagues show that 
in patients deemed ready for dis  continuing IABP 
support, microcirculatory ﬂ  ow in small vessels increases 
after ceasing IABP therapy. Th  e authors conclude that 
IABP impairs microvascular per  fusion in hemo  dy-
namically recovered patients. Th  ese impor  tant ﬁ  ndings 
not only highlight the need for optimal timing of weaning 
from IABP support but also demonstrate that global 
hemodynamics do not necessarily result in changes of 
microvascular perfusion [8,9]. In theory, IABP improves 
peak diastolic pressure and this may also translate into 
better microcirculation. Although suﬃ   cient  cardiac 
output and arterial pressure are prerequisites for ade-
quate microvascular perfusion, their relationship is very 
complex. Changes in micro  vascular vessel density and 
ﬂ  ow, their heterogeneity, autoregulation, and response to 
therapeutic interventions might be dissociated from 
systemic eﬀ  ects [2,9]. Furthermore, with the knowledge 
of the study by Munsterman and colleagues, it is 
obviously important to realize that, depending on the 
stage of the disease course, an intervention has diﬀ  erent 
eﬀ  ects on the microcirculation.
Modern therapy of CS consists of an adequate regime 
with revascularization, drug treatment, and mechanical 
support [10]. Although there is no question about the 
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needed to improve outcomes and understand the 
microcirculation as a therapy target and not as a silent 
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© 2010 BioMed Central Ltdsurvival advantage of early revascularization and its 
beneﬁ  cial consequences for the macrocirculation, there is 
no systematic study on its eﬀ  ects on microcirculation. 
However, revascularization reverses the spiral of 
progressive left ventricular dysfunction and therefore is 
understood to improve the microcirculation.
Diﬀ  erent drugs, particularly ﬂ  uids, vasopressors, ino-
tropes, levosimendan, and vasodilators, inﬂ  uence  the 
hemodynamics of patients with CS. Th  e administration 
of ﬂ   uids in CS is based mainly on pathophysiological 
considerations and has not been studied in adequate 
randomized clinical trials. No data regarding ﬂ  uid 
adminis  tration and microcirculatory changes in the 
setting of CS are available. Similar to ﬂ  uid administration, 
the choice of vasopressor and inotropic therapy is based 
mainly on individual experience and institutional policy; 
furthermore, this choice diﬀ   ers between guidelines. 
However, vasopressors might be able to stabilize the 
mean arterial pressure, but their use has negative 
consequences for the perfusion within microvasculature 
[11]. In small observatory studies, beneﬁ  cial eﬀ  ects on 
microcirculatory indices in CS have been described for 
levosimendan and nitro  glycerin [5,12].
Owing to the lack of evidence for the use of IABP in CS 
after successful revascularisation of occluded infarct 
vessels, its role remains controversial. To date, there is no 
adequately powered randomized clinical trial available, 
and knowledge is based on observational trials or trials 
before the era of primary PCI. IABP support improves 
microvascular ﬂ  ow in unstable patients; however, diﬀ  er  ent 
time points of the disease seem to be of importance [6,9].
Figure 1 summarizes therapeutic strategies aﬀ  ecting 
micro  vascular perfusion in CS. All interventions should 
be evaluated for their eﬀ  ect at the microcirculatory level. 
Microcirculatory evaluations need to be part of random-
ized controlled trial protocols. Guiding inter-individual 
modern therapy of CS with in vivo visualization tools 
may allow a more speciﬁ   c and appropriate therapy 
regime and improve outcomes. More eﬀ  ort is needed to 
understand the microcirculation as a therapy target and 
not as a silent bystander.
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